Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Transforming Methylated Nucleic Acids into Prostate Tumor Biomarkers

By BiotechDaily International staff writers
Posted on 06 Apr 2014
High quality oligonucleoside reagents and detection kits are facilitating research on methylated DNA and its relation to the molecular mechanisms that drive development of prostate cancer.

In the March 31, 2014, online edition of the Integrated DNA Technologies (Coralville, IA, USA) newsletter DECODED, Dr. Antoinette Perry, senior research fellow at the Institute of Molecular Medicine (Dublin, Ireland), described how use of materials supplied by Integrated DNA Technologies (IDT) facilitated her research team's study of prostate cancer.

Research in Dr. Perry’s laboratory is directed at understanding how changes in DNA methylation of coding and non-coding RNA genes are involved in driving prostate carcinogenesis. The investigators exploit specific epigenetic changes for early, noninvasive detection of aggressive prostate cancer. In the process, they hope to develop predictive epigenetic biomarkers—focusing both on circulating free nucleic acids and exosomes—that can be quantified by simple, liquid biopsy. Ultimately, they hope to use these biomarkers to develop a noninvasive test that will distinguish high-risk from lower-risk prostate tumors.

Among the tools being used are IDT PrimeTime qPCR Assays and ZEN Double-Quenched Probes. These probes increase the accuracy and reliability of 5’ nuclease qPCR experiments. They contain an internal quencher only nine bases from the 5’ fluorescent label. This shortened distance, particularly when combined with the standard 3’ quencher, significantly decreases background fluorescence and increases sensitivity. Since, the initial background fluorescence signal is much lower than with traditional probes, it is much easier to detect subsequent changes and, therefore, functionally increases assay sensitivity.

Integrated DNA Technologies is one of the largest suppliers of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development.

Related Links:
Integrated DNA Technologies
Institute of Molecular Medicine



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.